1. Home
  2. COPR vs SER Comparison

COPR vs SER Comparison

Compare COPR & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Copper Corporation Common Stock

COPR

Idaho Copper Corporation Common Stock

HOLD

Current Price

$2.35

Market Cap

60.1M

Sector

N/A

ML Signal

HOLD

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$1.80

Market Cap

56.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COPR
SER
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.1M
56.4M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
COPR
SER
Price
$2.35
$1.80
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
★ 70.3K
32.5K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $609,174.00
$130,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 132.14
52 Week Low
$2.05
$1.22
52 Week High
$4.16
$5.25

Technical Indicators

Market Signals
Indicator
COPR
SER
Relative Strength Index (RSI) 25.16 36.41
Support Level $2.05 $1.73
Resistance Level $3.63 $2.26
Average True Range (ATR) 0.30 0.11
MACD -0.11 -0.00
Stochastic Oscillator 8.11 22.22

Price Performance

Historical Comparison
COPR
SER

About COPR Idaho Copper Corporation Common Stock

Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: